

CUTIS LAXA: A NOVEL CLASSIFICATION AND GENERAL MANAGEMENT GUIDELINES

BERT CALLEWAERT, MD, PhD

CENTER FOR MEDICAL GENETICS, GHENT UNIVERSITY HOSPITAL



CTD teaching day
April 24th, 2024
London North West
University – NHS Trust



Cutis laxa: clinical hallmark

Heterogeneous group of connective tissue disorders characterized by redundant, loose, sagging and inelastic skin and variable systemic involvement




Cutis Laxa




Hyperextensible skin
(Classic EDS)

Cutis laxa: elastic fiber fragmentation


Control




ADCL



Cutis laxa: Classification




ELASTIC FIBERS



MICROFIBRIL





MICROFIBRIL + ELASTIN
= ELASTIC FIBER



- Inherited EFD → synthesis and/or assembly of elastic fibers: Genetics
- Acquired EFD → destruction of normal elastic fibers: Genetics - Environment

Note: ageing process / emphysema / aortic dilatation

CUTIS LAXA: DIVERSE PRESENTATIONS



Mendelian disease


Genomic variability



Environment influences







Elastic fiber
Acquired disease

WHY ARE THERE SO MANY PRESENTATIONS IN CUTIS LAXA?










Cutis laxa: Classification in progress...

Cutis laxa:
> 40 OMIM entries

Main clinical manifestation

Major Criteria

Minor Criteria






Own database (185)



Systematic review: 840 cases


Cutis laxa: a meaningful classification

Main clinical manifestation





Cutis laxa: a meaningful classification

Main clinical manifestation



Correct classification 95% ~ Management



Pulmonary/arterial involvement



“Cutis laxa + Emphysema”

“Benign”

→ *ELN* (ADCL tI)

→ *FBLN5* (type Ia)

→ *LTBP4* (type Ic)

“Cutis laxa + Arterial tortuosity”

→ *FBLN4* (type Ib)

→ *SLC2A10*: Arterial tortuosity syndrome

Pulmonary/arterial involvement

Generalized cutis laxa – “benign” (ADCL tI)



BUT:

ARD ~ 55%

Emphysema ~ 35%



Callewaert et al, 2011

Hadj-Rabia, Callewaert et al, 2013

Pulmonary/arterial involvement

Generalized cutis laxa – “benign”



	A	G	Q	F	P	L	G	G	V	A	A	R
WT:	GCC	GGG	CAG	TTC	CCA	CTT	GGA	GGA	GTG	GCA	GCA	AGA
MT:	GCC	GGG	CAG	TTC	CCA	CTT	GGA	GGA	GTG	GCA	GCA	AGA
	A	G	Q	F	P	L	G	G	V	A	A	R

	P	G	F	G	L	S	P	I	F	P	G	G
WT:	CCT	GGC	TTC	GGA	TTG	TCT	CCC	ATT	TTC	CCA	GGT	GGG
MT:	CCT	GGC	TTC	GGA	TTG	TCT	CCC	ATT	TTC	CAG	GTG	GGG
	P	G	F	G	L	S	P	I	F	Q	V	G

	A	C	L	G	K	A	C	G	R	K	R	K
WT:	GCC	TGC	CTG	GGG	AAA	GCT	TGT	GGC	CGG	AAG	AGA	AAA
MT:	CCT	GCC	TGG	GGA	AAG	CTT	GTG	GCC	GGA	AGA	GAA	AAT
	P	A	W	G	K	L	V	A	G	R	E	N

C-terminal frameshift mutations in *ELN*

→ elongated protein

→ C-terminal missense sequence.

	*
WT:	TGA
MT:	GAg ctt cct agg acc cct gac tca cga cct cat caa
	D L P R T P D S R P H Q

MT:	cgt tgg tgc tac tgc ttg gtg gag aat gta aac cct
	R W C Y C L V E N V N P



MT:	ttg <u>taa</u>
	L *

Pulmonary/arterial involvement

Generalized cutis laxa – “benign”



C-terminal frameshift mutations in *ELN*
→ elongated protein
→ C-terminal missense sequence.



control

ADCL

Pulmonary/arterial involvement



“Cutis laxa + Emphysema”

→ *FBLN5* (type Ia)

→ *LTBP4* (type Ic): URDS



Callewaert et al, 2013
Loeys et al, 2006

Pulmonary/arterial involvement




“Cutis laxa + Emphysema”

→ *FBLN5* (type Ia)

→ *LTBP4* (type Ic): URDS

GI / GU diverticula



Pulmonary/arterial involvement

Callewaert et al, 2008

Renard, Callewaert, et al, 2011

Kaplanayil et al, 2012



“Cutis laxa + Arterial tortuosity”

➔ *FBLN4* (type Ib)


➔ *SLC2A10*: Arterial tortuosity syndrome

Pulmonary/arterial involvement

Callewaert et al, 2008

Renard, Callewaert, et al, 2011

Kaplanayil et al, 2012



“Cutis laxa + Arterial tortuosity”

→ *FBLN4* (type Ib)

→ *Tortuosity, coA (isthmus)*

→ *Aneurysms*

→ *Osteopenia*

→ *Marfanoid skeletal features*

Pulmonary/arterial involvement

Callewaert et al, 2008

Beyens et al, 2018



“Cutis laxa + Arterial tortuosity”



➔ *SLC2A10*: Arterial tortuosity syndrome

➔ No dissections, but ischemic complications (CNS, kidney, bowel)

➔ Diaphragmatic hernia

➔ IRDS



➔ Corneal thinning



Pulmonary/arterial involvement



“Cutis laxa + Arterial tortuosity”



Prevalence

FBLN4





SLC2A10

Aneurysms/dissections
Cardioresp. failure


Novel entity: *EMILINI* loss-of-function mutations

Unexplained arterial tortuosity and fractures ~ resembling *FBLN4* related CL




Adamo et al, 2022

Role in extracellular matrix functioning




Cardiovascular imaging

Family 1



Family 2



Family 3



Tortuosity

4/4

ARD

2/4

Stenoses


1/4

Abnormal implantation of aortic branches

2/4

Cardiovascular imaging

Family 1



Family 2



Family 3



Skeletal imaging

Family 1



Family 2




Family 3

Fractures

3/4

>> neonatal
parietal
ribs
limbs

Histological analysis of *EMILINI* deficient aortic tissue



Aortic tissue of *EMILINI* or *FBLN4* deficient individuals shows severe medial degenerative changes





Ultrastructural evaluation of *EMILIN1* or *FBLN4* deficient human skin

Control



F3:II-1

F1:II-1


FBLN4



Defective EF assembly in *Emilin1* deficient human fibroblasts




EMILIN function: Summary





LOX is 'key' in arterial tortuosity syndromes: direct evidence

Cutis laxa
Arterial tortuosity
Osteopenia / fractures



McKenzie et al, 2021



LTBPI-related Cutis laxa: short stature - craniosynostosis

Pottie et al, 2021

Cutis laxa

Dysmorphisms



Skeletal patterning

Craniosynostosis


Brachydactyly

Short stature

Variable heart defects



LTBP1-related Cutis laxa: short stature - craniosynostosis



CL with skeletal/neurological involvement

ARCL type 2a/b




ARCL type 3a/b

Wrinkly skin syndrome





Debré type cutis laxa

Neurocutaneous disorder

De Barsy syndrome



CL with skeletal/neurological involvement




No ocular involvement
No IUGR
Abnormal glycosylation



Corneal clouding/Cataract
IUGR
Normal glycosylation patterns

- ➔ *ATP6V0A2* (type IIa)
- ➔ *ATP6V1E1* / *ATP6V1A*

- ➔ *PYCR1* (ARCL type IIb / IIIb)
- ➔ *ALDH18A1* (Progeroid dominant, ARCL IIIa)



CL with skeletal/neurological involvement



Al-Gazali 2001
Rajab 2008
Huchtagowder et al, 2009
Beyens, ..., Callewaert, 2018


No ocular involvement, no IUGR
Abnormal glycosylation

(microcephaly, Cobblestone brain,
late closing fontanelles)

→ *ATP6V0A2* (type IIa)

→ *ATP6V1E1* / *ATP6V1A*

Van Damme T, ... Callewaert B, Wevers R, 2017



ARCL t2
(Debré)

Wrinkly skin
syndrome

CL with skeletal/neurological involvement: a novel ATPase defect



Contractures, Hip dysplasia
Marfanoid - Pneumothorax
Aortic root dilatation
Cardiac hypertrophy
Variable NMD/gyral abno

Van Damme et al, 2017

CL with skeletal/neurological involvement: a novel ATPase defect



ATP6V1E1


c.383T>C
p.(Leu128Pro)



ATP6V1E1

c.634C>T
p.(Arg212Trp)

CL with skeletal/neurological involvement: a novel ATPase defect



Marfanoid, ARD, tortuous aortic arch, VSD

Thin corpus callosum

Polymicrogyria, Sept. Pellucidum defect, Ventriculomegaly, White matter gliosis

Delayed NMD

CL with skeletal/neurological involvement: a novel ATPase defect







ATP6V1A
c.215G>A
p.Gly72Asp

ATP6V1A
c.2012C>T
p.Gly72Asp

ATP6V1A
c.215G>A
p.Arg338Cys



V-ATPase defects cause a CDG type 2

Transferrin
isoelectrofocusing




■ N-Acetylglucosamine ● mannose ● galactose ◆ sialic acid

V-ATPase defects affect vesicular trafficking




Control

ATP6V0A2



ATP6V1E1

ATP6V1A



Knockout model
Pottie et al, 2022




Wild-type fish

Heterozygous fish

Homozygous fish



CL with skeletal/neurological involvement



No ocular involvement

No IUGR


Abnormal glycosylation

- ➔ *ATP6V0A2* (type IIa)
- ➔ *ATP6V1E1* / *ATP6V1A*


Ocular involvement / IUGR

Normal glycosylation patterns

- ➔ *PYCR1* (ARCL type IIb / IIIb)
- ➔ *ALDH18A1* (Progeroid dominant, ARCL IIIa)



CL with skeletal/neurological involvement: Proline Synthesis Defects




PYCRI

ALDH18A1

$\Delta\Psi \downarrow$

Apoptosis $\uparrow$



Proline Synthesis Defects: spectrum encompassing de Bary syndrome

Severity

PYCR1



Reversade et al, 2009

de Bary sy



ALDH18A1



Skidmore et al, 2011
Fischer-Zirnszak, Callewaert et al, 2014

**Dwarfism, oligophrenia and degeneration of the elastic tissue
in skin and cornea. A new syndrome?¹**

A. M. DE BARY, E. MOENS and L. DIERCKX

Received on March 13, 1968



IUGR – FTT
Relative macrocephaly
Cataract
NMD, spasticity, chorea



NMR: tortuosity of the ICA



PYCR1

normal

ALDH18A1


het c.412C>T

(p.Arg138Trp)


Del/dup analysis normal

De novo





Human P5CS	120	GKQRLRHEILLSSQSV	R QALHSGQNQLKEMAI	PVLEARACA
Chick P5CS	125	GKQRLRHEILLSSQSV	R QALHSGQSQLKDMAI	PVLEARACA
Fish P5CS	100	GKQRLRHEILLSSQSV	R QALHSGQNQLKDMSLPV	LEARACA
D. melanog. P5CS	106	GKQKLAQELLMSLSM	R ETLNPKDS--	KEFDGATLEPRAAA
C. elegans P5CS	131	GRQKLRQELVMSMSM	R QTLRGP-----	SGMTADKRACA
E.Coli GK	53	GREHLGYPEL-----	-----	PATIASKQLLA
Similarity		*:::*	:	. : *




ALDH18A1


p.Arg138Trp
p.Arg138Leu
p.Arg138Gln

All *de novo*


Superresolution microscopy



$C^{13}N^{15}$ glutamic acid labelling



X-linked recessive cutis laxa



ATP7A (Cu^{2+}) transporter

X-linked distal motor neuropathy

Occipital horn syndrome

Menkes disease


Serum Concentration	Menkes Disease ¹	Occipital Horn Syndrome	<i>ATP7A</i> -Related Distal Motor Neuropathy	Normal
Copper	0-55 $\mu\text{g/dL}$	40-80 $\mu\text{g/dL}$	80-100 $\mu\text{g/dL}$	70-150 $\mu\text{g/dL}$; (birth - 6 mos: 20-70 $\mu\text{g/dL}$)
Ceruloplasmin	10-160 mg/L	110-240 mg/L	240-310 mg/L	200-450 mg/L; (birth - 6 mos: 50-220 mg/L)

Kahler, GeneReviews

Beyens et al, 2019


De Feyter et al, 2023

X-linked recessive cutis laxa




ATP7A related transporters

X-linked distal motor neuropathy
Occipital horn syndrome
Menkes disease











Summary (I)

Cutis Laxa




95% of patients are
classified correctly

Summary (II)



Take Home message



Acknowledgements

CMGG

Aude Beyens

Maxim Verlee

Michiel Vanhooydonck

Lore Pottie

Lisa Caboor

Karolien Aelbrecht

Sofie Symoens

Patrick Sips

Cologne, Germany

Gerhard Sengle

Berlin, Germany

Björn Fischer-Zimzak

Göttingen, Germany

Uwe Kornak

Pittsburg, USA

Zsolt Urban

Paris, France

Christine Bodemer

Smail Hadj-Rabia

Perth, Australia

Fiona McKenzie

Istanbul, Turkey

Elif Yilmaz

Alper Gezdirici

Nijmegen, The Netherlands

Ron Wevers

Tatjana Gardeitchik

Referring physicians

All families !!!



European
Reference
Networks

